'SPACs Attack' Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines
- ByBenzinga-
Last week featured five announced SPAC deals and several rumors. The week also ...Full story available on Benzinga.com
Last week featured five announced SPAC deals and several rumors. The week also ...Full story available on Benzinga.com
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks(Biotech Stocks Hitting 52-week Highs May 4)AbbVie Inc. (NYSE: ABBV)BioLineRx...
Arbutus Biopharma (ABUS): Q1 GAAP EPS of -$0.21 beats by $0.02.Revenue of $2.11M (+41.6% Y/Y) misses by $1.25M.Cash, cash equivalents and investments totaling $132.0 million as of...
The S&P and NASDAQ took small steps back from record highs on Tuesday in preparation for a deluge of Big Tech data that began after the bell. Investors are feeling pretty...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 305.97 | 314.58 | 304.83 | -13.11 | -4.11% | 24.09M | NASDAQ | |||
| 2,291.75 | 2,331.00 | 2,284.54 | -60.18 | -2.56% | 1.54M | NASDAQ | |||
| 219.53 | 222.87 | 218.56 | -5.78 | -2.57% | 17.18M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 143.22 | 161.59 | 143.00 | -17.89 | -11.10% | 4.78M | NYSE | |||
| 18.47 | 19.30 | 18.18 | -1.28 | -6.48% | 103.73M | NYSE | |||
| 64.00 | 69.29 | 64.00 | -3.90 | -5.74% | 7.98M | NYSE | |||
| 17.95 | 19.59 | 17.85 | -1.66 | -8.47% | 16.75M | NYSE | |||
| 6.72 | 7.08 | 6.60 | -0.24 | -3.45% | 9.49M | NYSE | |||
| 1.14 | 1.23 | 1.13 | -0.0500 | -4.20% | 14.82M | NYSE | |||
| 15.80 | 16.99 | 15.77 | -0.59 | -3.60% | 6.87M | NYSE | |||
| 7.74 | 7.96 | 7.71 | 0.00 | 0.00% | 18.16M | NYSE | |||
| 0.8155 | 0.00 | 0.00 | -0.0194 | -2.32% | 2.06M | NYSE | |||
| 68.51 | 70.48 | 68.45 | -0.66 | -0.95% | 974.13K | NYSE | |||
| 4.98 | 5.15 | 4.96 | -0.12 | -2.35% | 56.02M | NYSE |
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing cure for people with chronic hepatitis B virus (HBV) infection. Its product pipeline is focused on finding curative combination regimen for chronic HBV infection, with the objective of developing a suite of products that intervene at different points in the viral life cycle and reactivate the host immune system. It is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. The Company’s HBV product pipeline includes ribonucleic acid (RNA) interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit programmed death-ligand one (PDL1) and oral HBV RNA destabilizers. Its subsidiaries include Arbutus Inc and Arbutus Biopharma US Holdings, Inc.